We are live on ! Find out more
EVFM

Evofem Biosciences, Inc. Common Stock

Delisted

EVFM was delisted on the 10th of August, 2022.

24 hedge funds and large institutions have $1.74M invested in Evofem Biosciences, Inc. Common Stock in 2015 Q4 according to their latest regulatory filings, with 7 funds opening new positions, 6 increasing their positions, 4 reducing their positions, and 12 closing their positions.

New
Increased
Maintained
Reduced
Closed

50% more repeat investments, than reductions

Existing positions increased: 6 | Existing positions reduced: 4

17% less funds holding

Funds holding: 2924 (-5)

42% less first-time investments, than exits

New positions opened: 7 | Existing positions closed: 12

92% less capital invested

Capital invested by funds: $22.1M → $1.74M (-$20.3M)

100% less funds holding in top 10

Funds holding in top 10: 10 (-1)

Holders
24
Holders Change
-5
Holders Change %
-17.24%
% of All Funds
0.63%
Holding in Top 10
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-100%
% of All Funds
New
7
Increased
6
Reduced
4
Closed
12
Calls
Puts
Net Calls
Net Calls Change
Name Holding Trade Value Shares
Change
Change in
Stake
CCM
26
Consonance Capital Management
New York
-$987K -1,359 Closed
Alyeska Investment Group
27
Alyeska Investment Group
Illinois
-$917K -1,262 Closed
AC
28
Amici Capital
New York
-$760K -1,047 Closed
SIM
29
Spark Investment Management
New York
-$264K -364 Closed
TC
30
TFS Capital
Pennsylvania
-$217K -299 Closed
Goldman Sachs
31
Goldman Sachs
New York
-$159K -218 Closed
EEG
32
E.E. Geduld
-$81K -111 Closed
Bank of Montreal
33
Bank of Montreal
Ontario, Canada
-$54K -75 Closed
EWM
34
Edge Wealth Management
New York
-$8K -11 Closed
Acadian Asset Management
35
Acadian Asset Management
Massachusetts
-$2K -2 Closed

EVFM Hedge Fund Activity: Q4 2015 in Review

24 of the 3,812 institutional investors tracked by Wall St. Rank reported a position in Evofem Biosciences, Inc. Common Stock (EVFM) for Q4 2015, worth a combined $1.74M — down 92% from $22.1M a quarter earlier.

Sellers outnumbered buyers: 12 funds closed out of EVFM and 7 opened new positions — a net loss of 5 holders — while 4 trimmed existing stakes and 6 added.

The largest buyer was Vanguard Group, adding an estimated $512K. The largest seller was Clarus Ventures, exiting entirely with an estimated $8.65M sold.

  • 24 institutional investors held Evofem Biosciences, Inc. Common Stock (EVFM) as of Q4 2015, down from 29 in Q3 2015.
  • Funds reported $1.74M of Evofem Biosciences, Inc. Common Stock stock for Q4 2015, down 92% quarter-over-quarter.
  • 7 funds opened new Evofem Biosciences, Inc. Common Stock positions in Q4 2015 and 12 closed out, a net change of -5 holders.
  • The largest Evofem Biosciences, Inc. Common Stock buyer in Q4 2015 was Vanguard Group, an estimated $512K added.
  • The largest Evofem Biosciences, Inc. Common Stock seller in Q4 2015 was Clarus Ventures, an estimated $8.65M sold.

Based on aggregated 13F filings for Q4 2015.